MedAdvisor CEO and managing director, Rick Ratliff, said, "We are now sharpening our focus on the US business. While near-term market headwinds persist, we remain confident in the strength of our platform, the depth of our client relationships, and the strategic investments positioning us for long-term growth."
-
Latest News
More companies are exercising their rights, and they are perfectly entitled
Setting aside the lack of utility of these documents, which provide virtually incomprehensible explanations for demanding price reductions, the information they contain belongs to the sponsor companies, who have every right to delay or prevent their publication.
-
Latest News MedAdvisor restates focus on US following completion of ANZ business sale July 8, 2025
-
Latest News South Australia expands flu vax availability in response to record outbreak July 8, 2025The South Australian Government has responded to a significant seasonal flu outbreak by announcing it will fund pharmacies to administer the vaccines to children aged six months to five years.
-
Latest News IGB signals the need to renegotiate the expiring statutory pricing framework July 6, 2025The critical and key point is that the anniversary statutory price reductions legislated as a result of agreements are time-limited, meaning they expire, making a new negotiation almost inevitable and giving the industry leverage.
-
Latest News UK's ten-year plan backs faster access, but industry laments lack of investment July 7, 2025The British pharmaceutical industry has cautiously welcomed a new ten-year plan for the country's National Health Service, which shares some characteristics with Australia's HTA Review.
-
Latest News Pharmac minister prepares to deliver letter of expectations July 7, 2025New Zealand's Deputy Prime Minister and Associate Health Minister, David Seymour, will issue an updated letter of expectations to Pharmac before the end of July.
-
Latest News What's the point of pretending that Australia doesn't free-ride on US innovation? July 3, 2025Not only does Australia free-ride on US funded innovation, it revels in it, while maintaining a broader life sciences strategy premised on almost total dependence on returns from the country's large and generous healthcare market.
-
Latest News Framework pushes genomics funding to a review that is mostly silent on it July 3, 2025The framework acknowledges the use of genomics in cancer care, including targeted therapies, but it bypasses any specific consideration of funding systems and processes by deferring it to a review that is mostly silent on the issue.
-
Latest News Medicines Australia backs focus on listings and productivity in government brief July 3, 2025Medicines Australia says it welcomes the Department of Health, Disability and Ageing's "clear and positive recommendations to Government, to focus on implementation and delivery of the next critical phase for the HTA Review, within the recently released Incoming Government Brief."
-
Australian Biotech AusBiotech seeking a head of investment to drive sector growth July 3, 2025AusBiotech, the national representative organisation of Australia’s life sciences industry, is seeking a head of investment.
-
Latest News Draft 'National Health Genomics Policy Framework' out for consultation July 3, 2025While the report acknowledges the use of genomics in cancer care, including targeted therapies, it does not provide specific recommendations to more broadly integrate its use beyond vague references to the Health Technology Assessment Review.
-
Latest News GBMA announces planned departure of long-standing CEO July 2, 2025The Generic and Biosimilar Medicines Association has announced that its chief executive, Marnie Peterson, who has held the position for seven years, will depart the organisation at the end of 2025.
-
Latest News MedAdvisor announces agreement confirming the sale of Australian business July 3, 2025MedAdvisor has now announced a binding share sale and purchase agreement to sell its Australian and New Zealand business division and associated intellectual property to Jonas Software.
-
Latest News The industry backs productivity focus for the Albanese Government's second term July 2, 2025Productivity is a primary focus at the start of the Albanese Government's second term, including in the health sector, and the industry is planning to contribute.
-
Latest News New treatment option for early breast cancer at high risk of recurrence July 2, 2025Matt Zeller, Novartis country president for Australia and New Zealand, said, “We welcome the PBS listing of KISQALI for node-positive patients at high risk of cancer recurrence. Importantly, this milestone provides the EBC community with more treatment choices, but we recognise there is still more work to be done."
-
Latest News Expanded listing for Bristol Myers Squibb's PD-1 to include bladder cancer July 2, 2025“This is a welcome additional treatment option for this patient population and reinforces our goal of delivering new options to patients living with difficult-to-treat cancers," said Owen Smith, the general manager of Bristol Myers Squibb Australia and New Zealand.
-
Latest News New Zealand's Medsafe and Pharmac directed to explore AI use to expedite access July 2, 2025Associate Health Minister, David Seymour, has directed the country's regulator and reimbursement agency to explore the use of artificial intelligence to expedite their processes.
-
Latest News Wesfarmers Health launches pilot pharmacy format, InstantScripts Pharmacy Health Hub July 2, 2025Wesfarmers Health chief customer officer Richard Pearson said, “Trialling new retail formats is one of the ways we are delivering simpler, more affordable and easier to access health, beauty and wellness experiences."
-
Latest News The real question is why expectations were so high in the first place July 1, 2025Despite stakeholder angst over the health department's Incoming Government Brief, it contains few surprises, including its advice on the HTA Review and new funding mechanisms for PBS listings.
-
Latest News Takeda therapy now available through the PBS for serious viral infection July 1, 2025Takeda's LIVTENCITY (maribavir) is now available through the PBS for people with post-transplant cytomegalovirus infection and disease who are resistant, refractory or intolerant to one or more prior therapies.
Australian Biotech
-
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 -
PYC Therapeutics to progress polycystic kidney disease trial
July 7, 2025 -
AusBiotech seeking a head of investment to drive sector growth
July 3, 2025 -
Neurizon announces global agreement with Elanco for the commercialisation of NUZ-001
July 2, 2025 -
Prescient Therapeutics opens share purchase plan
July 2, 2025
Other Health
-
Kidney Health Australia urges those at risk to get checked
March 10, 2025 -
Sepsis survivors at high risk after hospital discharge, new figures reveal
March 5, 2025 -
New Zealand medtech start-up Avasa hits milestone in development of world’s first arterial coupler
February 24, 2025 -
Australia isn’t ready for the next cardiac epidemic, warns landmark heart valve disease report
February 17, 2025 -
BTC announced new partnership agreement with Corcym
December 9, 2024
Latest Video
New Stories
-
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News -
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 - - Australian Biotech -
PYC Therapeutics to progress polycystic kidney disease trial
July 7, 2025 - - Australian Biotech -
Pharmac minister prepares to deliver letter of expectations
July 7, 2025 - - Latest News -
UK's ten-year plan backs faster access, but industry laments lack of investment
July 7, 2025 - - Latest News